Kite Pharma’s Yescarta® Approved by the EC for Adults with Relapsed or Refractory Follicular Lymphoma

Kite Pharma - A Gilead Company
Gilead Sciences' (GILD) firm Kite Pharma, announced that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

Yescarta maintained its orphan medicinal product designation in this indication.
From . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.